http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110437149-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-472 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-02 |
| filingDate | 2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110437149-B |
| titleOfInvention | Natural naphthyl isoquinoline compound with antitumor activity, and composition and application thereof |
| abstract | The invention belongs to the field of biomedicine, and relates to a natural naphthyl isoquinoline compound with antitumor activity, a composition and application thereof. A compound of the formula I linked at the 1,3, 8-position and the 5-position of the formula II, orLinked by the 1,3, 6,8 position of formula I and the 7 position of formula II; the structures of the general formula I and the general formula II are respectively as follows: the compound and the composition provided by the invention can be used for treating and/or preventing tumor diseases by inhibiting EGFR (epidermal growth factor receptor) protein tyrosine kinase, particularly for treating non-small cell lung cancer or small cell lung cancer, can be developed into novel EGFR-TKI, and have wide application prospects. |
| priorityDate | 2019-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.